“…Triglyceride levels in patients with and without SVR differed only at follow-up (P = 0.028) [ 57 ]. A large German, observational, real-world study enrolled 10,390 patients who were treated with PegIFN-α2a/RBV and evaluated and prospectively followed them for cardiovascular and metabolic risk markers, concluding that in contrast to the presence of T2DM, which was a negative predictor of SVR, the presence of elevated total cholesterol levels was associated with higher SVR rates [ 58 ].…”